» Articles » PMID: 40008085

Role and Mechanism of Mitochondrial Ribosomal Proteins in Septic Myocardial Injury

Overview
Journal J Inflamm Res
Publisher Dove Medical Press
Date 2025 Feb 26
PMID 40008085
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the role of mitochondrial ribosomal proteins (MRPs) in the pathogenesis and progression of septic myocardial injury. Additionally, we aim to propose new technical strategies and experimental foundations for the prevention and treatment of septic myocardial injury.

Methods: Animal and cell models of septic myocardial injury were established. Aberrantly expressed MRPs were screened using transcriptome sequencing, and their expression was verified by RT-qPCR and Western blot. Subsequently, overexpressed and knockdown cell models of myocardial injury were constructed. The effects on CO I, PGC-1α, ATP content, ROS fluorescence intensity, mitochondrial membrane potential, and GSDMD were assessed, along with changes in caspase-4 and IL-1β expression levels.

Results: Transcriptome sequencing revealed a reduction in MRPs expression in mice with septic myocardial injury. Both RT-qPCR and Western blot analysis confirmed the decreased expression of MRPs in animal and cell models of septic myocardial injury. Furthermore, overexpression of both MRPS16 and MRPL47 mitigated the decrease in CO I and PGC-1α levels induced by septic myocardial injury. Additionally, overexpression of MRPS16 and MRPL47 alleviated the elevated levels of IL-1β, caspase-4, and GSDMD caused by septic myocardial injury.

Conclusion: The findings suggest that both MRPS16 and MRPL47 can mitigate mitochondrial injury by attenuating mitochondrial biosynthesis dysfunction, energy metabolism disorders, and Ca disturbances caused by septic myocardial injury. This ultimately reduces cellular damage and alleviates septic myocardial injury.

References
1.
Brown D, Perry J, Allen M, Sabbah H, Stauffer B, Shaikh S . Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2016; 14(4):238-250. PMC: 5350035. DOI: 10.1038/nrcardio.2016.203. View

2.
Sylvester J, Fischel-Ghodsian N, Mougey E, OBrien T . Mitochondrial ribosomal proteins: candidate genes for mitochondrial disease. Genet Med. 2004; 6(2):73-80. DOI: 10.1097/01.gim.0000117333.21213.17. View

3.
Jackson C, Huemer M, Bolognini R, Martin F, Szinnai G, Donner B . A variant in MRPS14 (uS14m) causes perinatal hypertrophic cardiomyopathy with neonatal lactic acidosis, growth retardation, dysmorphic features and neurological involvement. Hum Mol Genet. 2018; 28(4):639-649. DOI: 10.1093/hmg/ddy374. View

4.
Li Z, Wu B, Chen J, Ye N, Ma R, Song C . WWP2 protects against sepsis-induced cardiac injury through inhibiting cardiomyocyte ferroptosis. J Transl Int Med. 2024; 12(1):35-50. PMC: 11000860. DOI: 10.2478/jtim-2024-0004. View

5.
Huang G, Li H, Zhang H . Abnormal Expression of Mitochondrial Ribosomal Proteins and Their Encoding Genes with Cell Apoptosis and Diseases. Int J Mol Sci. 2020; 21(22). PMC: 7700125. DOI: 10.3390/ijms21228879. View